Cargando…
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
BACKGROUND: Tildrakizumab, an anti-IL-23, showed promising efficacy and safety profiles in two randomized clinical-trials (reSURFACE-1 and reSURFACE-2), comparing tildrakizumab superiority to placebo and etanercept. Due to its recent availability in clinical-practice, real-life data are still limite...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983574/ https://www.ncbi.nlm.nih.gov/pubmed/36873660 http://dx.doi.org/10.2147/CCID.S402183 |
_version_ | 1784900574349623296 |
---|---|
author | Ruggiero, Angelo Fabbrocicni, Gabriella Cacciapuoti, Sara Potestio, Luca Gallo, Lucia Megna, Matteo |
author_facet | Ruggiero, Angelo Fabbrocicni, Gabriella Cacciapuoti, Sara Potestio, Luca Gallo, Lucia Megna, Matteo |
author_sort | Ruggiero, Angelo |
collection | PubMed |
description | BACKGROUND: Tildrakizumab, an anti-IL-23, showed promising efficacy and safety profiles in two randomized clinical-trials (reSURFACE-1 and reSURFACE-2), comparing tildrakizumab superiority to placebo and etanercept. Due to its recent availability in clinical-practice, real-life data are still limited. OBJECTIVE: To assess the efficacy and safety of tildrakizumab in a real-world-practice in patients suffering from moderate-to-severe psoriasis. METHODS: A 52-week observational retrospective study enrolled patients suffering from moderate-to-severe plaque-psoriasis, starting tildrakizumab treatment. RESULTS: A total of 42 patients were included in the study. Mean PASI showed a significant reduction at each follow-up (p<0.001), reducing from 13.5±5.9 at baseline, 2.8±3.8 at week-28, resulting stable up to week-52. High rates of patients reached both PASI90 and PASI100 responses at both week 16 (PASI90: 52.4%, PASI100: 33.3%) and week 28 (PASI90: 76.1%, PASI100: 61.9%), maintaining these up to week 52 (PASI90: 73.8%, PASI100: 59.5%). The impact of treatment on patient’s quality of life has been evaluated with DLQI, which showed a significant reduction during follow-ups. CONCLUSION: Our data confirm tildrakizumab as an effective and generally safe treatment for the management of moderate-to-severe psoriasis, with high rates of both PASI90 and PASI100 responses, and very few reported adverse events, up to 52 weeks of follow-up. |
format | Online Article Text |
id | pubmed-9983574 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-99835742023-03-04 Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study Ruggiero, Angelo Fabbrocicni, Gabriella Cacciapuoti, Sara Potestio, Luca Gallo, Lucia Megna, Matteo Clin Cosmet Investig Dermatol Original Research BACKGROUND: Tildrakizumab, an anti-IL-23, showed promising efficacy and safety profiles in two randomized clinical-trials (reSURFACE-1 and reSURFACE-2), comparing tildrakizumab superiority to placebo and etanercept. Due to its recent availability in clinical-practice, real-life data are still limited. OBJECTIVE: To assess the efficacy and safety of tildrakizumab in a real-world-practice in patients suffering from moderate-to-severe psoriasis. METHODS: A 52-week observational retrospective study enrolled patients suffering from moderate-to-severe plaque-psoriasis, starting tildrakizumab treatment. RESULTS: A total of 42 patients were included in the study. Mean PASI showed a significant reduction at each follow-up (p<0.001), reducing from 13.5±5.9 at baseline, 2.8±3.8 at week-28, resulting stable up to week-52. High rates of patients reached both PASI90 and PASI100 responses at both week 16 (PASI90: 52.4%, PASI100: 33.3%) and week 28 (PASI90: 76.1%, PASI100: 61.9%), maintaining these up to week 52 (PASI90: 73.8%, PASI100: 59.5%). The impact of treatment on patient’s quality of life has been evaluated with DLQI, which showed a significant reduction during follow-ups. CONCLUSION: Our data confirm tildrakizumab as an effective and generally safe treatment for the management of moderate-to-severe psoriasis, with high rates of both PASI90 and PASI100 responses, and very few reported adverse events, up to 52 weeks of follow-up. Dove 2023-02-27 /pmc/articles/PMC9983574/ /pubmed/36873660 http://dx.doi.org/10.2147/CCID.S402183 Text en © 2023 Ruggiero et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Ruggiero, Angelo Fabbrocicni, Gabriella Cacciapuoti, Sara Potestio, Luca Gallo, Lucia Megna, Matteo Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study |
title | Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study |
title_full | Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study |
title_fullStr | Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study |
title_full_unstemmed | Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study |
title_short | Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study |
title_sort | tildrakizumab for the treatment of moderate-to-severe psoriasis: results from 52 weeks real-life retrospective study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983574/ https://www.ncbi.nlm.nih.gov/pubmed/36873660 http://dx.doi.org/10.2147/CCID.S402183 |
work_keys_str_mv | AT ruggieroangelo tildrakizumabforthetreatmentofmoderatetoseverepsoriasisresultsfrom52weeksrealliferetrospectivestudy AT fabbrocicnigabriella tildrakizumabforthetreatmentofmoderatetoseverepsoriasisresultsfrom52weeksrealliferetrospectivestudy AT cacciapuotisara tildrakizumabforthetreatmentofmoderatetoseverepsoriasisresultsfrom52weeksrealliferetrospectivestudy AT potestioluca tildrakizumabforthetreatmentofmoderatetoseverepsoriasisresultsfrom52weeksrealliferetrospectivestudy AT gallolucia tildrakizumabforthetreatmentofmoderatetoseverepsoriasisresultsfrom52weeksrealliferetrospectivestudy AT megnamatteo tildrakizumabforthetreatmentofmoderatetoseverepsoriasisresultsfrom52weeksrealliferetrospectivestudy |